PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice.
about
Modulation of mitogen-activated protein kinase-activated protein kinase 3 by hepatitis C virus core proteinHepatitis C virus hijacks host lipid metabolismMechanisms of intrahepatic triglyceride accumulationMetabolic alterations and hepatitis C: From bench to bedsideContributions of transgenic mouse studies on the research of hepatitis B virus and hepatitis C virus-induced hepatocarcinogenesisHost-Targeting Agents to Prevent and Cure Hepatitis C Virus InfectionPathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogenHCV and Oxidative Stress: Implications for HCV Life Cycle and HCV-Associated PathogenesisMetabolic factors and chronic hepatitis C: a complex interplayMouse models for the study of HCV infection and virus–host interactionsHepatitis C Virus Nonstructural 4B Protein Modulates Sterol Regulatory Element-binding Protein Signaling via the AKT PathwayMolecular mechanisms of insulin resistance in chronic hepatitis COxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesisPolyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stressIntegrated analysis of mutation data from various sources identifies key genes and signaling pathways in hepatocellular carcinoma.Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation.Nutrigenomics therapy of hepatisis C virus induced-hepatosteatosis.Production and pathogenicity of hepatitis C virus core gene products.PPARalpha: energy combustion, hypolipidemia, inflammation and cancerHepatocarcinogenesis associated with hepatitis B, delta and C viruses.Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.Quinolinate Phosphoribosyltransferase is an Antiviral Host Factor Against Hepatitis C Virus Infection.Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinaseHepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouseRole of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet.Viral hepatocarcinogenesis.HCV 3a core protein increases lipid droplet cholesteryl ester content via a mechanism dependent on sphingolipid biosynthesis.The hepatitis C virus core protein inhibits adipose triglyceride lipase (ATGL)-mediated lipid mobilization and enhances the ATGL interaction with comparative gene identification 58 (CGI-58) and lipid dropletsDifferential regulation of cytotoxicity pathway discriminating between HIV, HCV mono- and co-infection identified by transcriptome profiling of PBMCs.Adipocyte-specific disruption of fat-specific protein 27 causes hepatosteatosis and insulin resistance in high-fat diet-fed mice.Increased incidence of aflatoxin B1-induced liver tumors in hepatitis virus C transgenic miceOncogenic potential of hepatitis C virus proteinsHepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis.Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.Hepatitis C virus-induced hepatocellular carcinomaHepatic Cerebroside Sulfotransferase Is Induced by PPARα Activation in MicePPARα Activation Protects against Anti-Thy1 Nephritis by Suppressing Glomerular NF-κB Signaling.PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs.Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy.Characterization of bioactive agents in five types of marketed sprouts and comparison of their antihypertensive, antihyperlipidemic, and antidiabetic effects in fructose-loaded SHRs.
P2860
Q24336062-77EAD9B6-7308-41E9-B5EF-89C865A4C573Q24652319-B7ACD27F-6F6F-41D5-95A9-EB389D52C8D2Q26773198-13CE47B4-4FCD-4746-BA61-B6BF219DE309Q26773261-6AD16603-6BC5-4F51-B2A4-9BE16F4DA5EAQ26775804-FC97C3B3-26FB-4099-8982-07FAB76E6E57Q26779128-031B8C4F-9DFD-434B-97F1-B1B07C7D8053Q26861095-A9B2FD24-2768-497B-9216-E866C288BF71Q26996778-42A58A33-CF5C-4002-AD65-A27B1D448681Q27011787-01DFCCF0-8833-4DEB-8D22-1D0CA6F89685Q27486807-69CC0CAF-2D35-4044-8CA2-8F693CAEBDF4Q27488294-8BFA136A-F74F-43AA-928D-F2280EAD7246Q27489665-BD94C1DD-9B86-4BFB-BC58-A8BD9A343CB1Q28075646-A56383F4-C54E-46C3-A5E1-89B683C2D02DQ28242949-83BE15F1-10EC-4E48-A637-2C195ED393CFQ30834745-87C79169-5462-416F-B353-6E6D11131AEEQ33491812-0FFD1F45-8614-48EA-8070-EC49B3908AB6Q33582787-7039F0FE-4E22-4982-908F-F43E3341C93FQ33780095-16A8CB98-E673-4CDA-A5F3-06D7D7312338Q33805104-A82FB3B8-44F1-43B0-9016-D65B264A517EQ33899640-1141ABE9-BD17-4147-913C-69CD4997FD74Q33904328-1BCA9FC5-54ED-4202-9A19-419FCB2E66D6Q33918411-7571E78C-A07B-4DCB-9796-9D962D10FAEAQ33953064-0E8CCBBA-35DF-4D94-87B0-BD5827D10FE5Q34009002-3C216B12-89F9-4698-9BD2-30E13B98574DQ34302360-DC180C01-0ABB-4E28-87DB-BB113200EFAEQ34617749-D08C3519-2A03-4F89-BFFC-A18CBE4C78D3Q34734158-89923900-0EF9-47A4-BCF0-1AD64959A23BQ34774442-1377499C-60A1-4690-A4C8-1778B8BA959BQ35033949-8D752A7A-5DC0-4EC0-A263-63AE23FF028CQ35048863-0AF50D85-11DC-40E1-9087-87E6BFC7E97AQ35179492-E6F0F54A-EF06-4668-A72F-28A396AA3F25Q35261292-40B26F54-DEF2-464D-A54A-45B0D95537BFQ35604983-F715E540-4DE2-4BDB-AA25-E4706F0DD76EQ35619104-15D8E479-97B4-487C-BC23-E5CCF67D45ECQ35824057-DC5DB393-0B3D-4389-A2FA-D29781A313FDQ35975150-A09A7E4F-662F-4ABD-BCD9-0CA623D458C4Q35997191-01389C8B-6992-45F2-A3B8-2877F3D19D14Q36253614-D35F4672-B3B9-4AFF-8F67-44C543A4AF2AQ36323842-51BA5C6F-4F15-40A1-A656-C8CA08E03DEFQ36458743-6306C186-82FE-4062-A9E5-0A335EF70364
P2860
PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
PPARalpha activation is essent ...... atocellular carcinoma in mice.
@ast
PPARalpha activation is essent ...... atocellular carcinoma in mice.
@en
type
label
PPARalpha activation is essent ...... atocellular carcinoma in mice.
@ast
PPARalpha activation is essent ...... atocellular carcinoma in mice.
@en
prefLabel
PPARalpha activation is essent ...... atocellular carcinoma in mice.
@ast
PPARalpha activation is essent ...... atocellular carcinoma in mice.
@en
P2093
P2860
P356
P1476
PPARalpha activation is essent ...... atocellular carcinoma in mice.
@en
P2093
Frank J Gonzalez
Kendo Kiyosawa
Kyoji Moriya
Naoki Tanaka
Toshifumi Aoyama
P2860
P304
P356
10.1172/JCI33594
P407
P577
2008-02-01T00:00:00Z